Lilly Launches Higher Dose Vials of Weight-Loss Drug
The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...
More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.
Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...
The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.
Cavazzoni stepped down from her role as head of the FDA’s main drug review office in mid-January. She will succeed Aida ...
Eli Lilly was second to the lucrative GLP-1 market for diabetes and obesity following its chief metabolic medicine rival Novo ...
Shares of Hims & Hers Health plunged Friday after the Food & Drug Administration said a shortage of the active ingredient in ...
The FDA said the shortage of Novo Nordisk's weight-loss drugs Wegovy and Ozempic is resolved. The move could limit cheaper compounded versions ...
The lawsuit claims the FDA's finding that there was no longer a shortage of the drugs' active ingredient semaglutide was ...
Eli Lilly kicks off 2025 with key licensing deals and M&A, boosting its position across therapeutic areas amid rising drug ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback